ZVS203e clinical trials
ZVS203e is named as an intervention in 3 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Early Phase 1. The sponsor with the most trials is Zhongshan Ophthalmic Center, Sun Yat-sen University (1). The most-studied condition is Retinitis Pigmentosa.
Patient leaflets for ZVS203e
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of ZVS203e
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation
NCT06952842 · ClinicalTrials.gov ↗ · Retinitis Pigmentosa
|
Phase 1/2 | Recruiting | Chigenovo Co., Ltd | China |
|
Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa
NCT05805007 · ClinicalTrials.gov ↗ · Retinitis Pigmentosa
|
Early Phase 1 | Recruiting | Peking University Third Hospital | China |
|
The Safety and Efficacy of ZVS106e in the Treatment of IRDs Caused by Biallelic Mutations in ABCA4
NCT07241169 · ClinicalTrials.gov ↗ · Stargardt
|
Early Phase 1 | Recruiting | Zhongshan Ophthalmic Center, Sun Yat-sen University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with ZVS203e
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Zhongshan Ophthalmic Center, Sun Yat-sen University | 1 |
| Chigenovo Co., Ltd | 1 |
| Peking University Third Hospital | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 3 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about ZVS203e trials
How many clinical trials are testing ZVS203e?
3 current trials in our China register name ZVS203e (also registered as ZVS106e) as a drug or biological intervention, as of the registry sync on 16 October 2026. Completed and withdrawn studies are not counted.
Are ZVS203e trials recruiting patients?
Yes. 3 of the 3 trials are recruiting: 3 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors ZVS203e clinical trials?
Zhongshan Ophthalmic Center, Sun Yat-sen University (1), Chigenovo Co., Ltd (1) and Peking University Third Hospital (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how ZVS203e works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ZVS203e works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ZVS203e (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 16 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.